Education & Training

Notable Recent Papers

Notable recent papers in the field are highlighted below.

PARADIGM: VenAza vs Intensive Chemo in fit AML (Fathi et al 2026)

ASCERTAIN-V: All-Oral Treatment in older AML (Roboz et al 2026)

The NCRI AML18 trial: CPX-351 vs DA_Mylotarg in non-adverse risk AML (Knapper et al 2026)

Latest international update for how to use MRD in clinical practice, developed by members of the ELN-DAVID MRD Working Party, including recommendations for ultra-high sensitivity FLT3 NGS MRD testing (Cloos et al 2025)

Treatment intensification with DA-Cladribine or FLAG-Ida for residual disease: AML18 (Russell et al 2025)

Molecular monitoring vs standard clinical care in younger older with AML: results from AML17 and AML19 (Potter et al 2025)

Molecular, clinical and therapeutic determinants of outcome in NPM1-mutated AML (Othman et al 2024)

Fractioned vs single-dose gemtuzumab in older patients with AML: AML18 (Freeman et al 2023)

The NCRI AML19 trial: CPX-351 vs FLAG-Ida in adverse karyotype AML and high-risk MDS (Othman et al 2023).

Meetings

AML Academy 2026, Birmingham

Yearly expert-led update on state of-the-art management of adult AML

17th-18th September 2026

AML Bites Journal Club Program

Coming soon; a national discussion group for review of the most interesting recent papers in the field.